Advertisement
Advertisement
APGE
Apogee Therapeutics, Inc. Common Stock
134.79
USDSponsored
+0.04
+0.03%
Aug 24, 15:59 UTC -4
Closed
After-Market
134.79
0.00
0.00%
APGE Earnings Reports
Positive Surprise Ratio
APGE beat 6 of 13 last estimates.
46%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$1.15
Implied change from Q2 26 (Revenue/ EPS)
--
/+1.77%
Implied change from Q3 25 (Revenue/ EPS)
--
/+3.60%
Apogee Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, APGE reported earnings of -1.13 USD per share (EPS) for Q2 26, missing the estimate of -1.09 USD, resulting in a -4.39% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.14% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -1.15 USD, with revenue projected to reach -- USD, implying an increase of 1.77% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.11
Actual
$0.35
Surprise
+198.38%
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Alpha Cognition Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.40
Surprise
-0.05%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
PDS Biotechnology Corporation Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.18
Surprise
-35.75%
FAQ
What were Apogee Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Apogee Therapeutics, Inc. Common Stock reported EPS of -$1.13, missing estimates by -4.39%, and revenue of $0.00, 0% as expectations.
How did the market react to Apogee Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -0.14%, changed from $134.84 before the earnings release to $134.65 the day after.
When is Apogee Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Apogee Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Apogee Therapeutics, Inc. Common Stock is expected to report EPS of -$1.15 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement